| Abstrakt: |
SAN DIEGO, May 30, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive: Dr. Ashok Srivastava, MD, Ph.D., MBA, to their scientific advisory board. Dr. Srivastava's notable achievements include contributions to 21-IND (Investigational New Drug) filings and 7-NDA (New Drug Application) filings, with all IND's and NDA's being exclusively for cancer drugs. He was also a pivotal player in the acquisition and merger of a biotech drug organization by Daiichi-Sankyo Pharmaceuticals. Dr. Srivastava's experience will greatly benefit Calidi Bio as the company advances the growth of their cell-based oncolytic virus delivery platform. [ABSTRACT FROM PUBLISHER] |
